From promises to policies: is big pharma delivering on transparency?
Description
As increasing numbers of pharmaceutical companies establish policies for granting third party access to their clinical trial data, the onus shifts to those ready to begin sifting through the dataCitation
Doshi, P. (2014). From promises to policies: is big pharma delivering on transparency? BMJ 2014;348:g1615. DOI: https://doi.org/10.1136/bmj.g1615Keyword
research transparencydata sharing
data sharing restrictions
Drug Industry
Clinical Trials as Topic
Information Dissemination--methods
Identifier to cite or link to this item
http://hdl.handle.net/10713/6603ae974a485f413a2113503eed53cd6c53
10.1136/bmj.g1615
Scopus Count
Collections
Related articles
- Getting the attention of Big Pharma. And Big Pharma is listening.
- Authors: Haugh R
- Issue date: 2003 Oct
- The dominance of big pharma: power.
- Authors: Edgar A
- Issue date: 2013 May
- Lead Essay: Money, Equity and Access to Medicines.
- Authors: Ghinea N, Lipworth W, Kerridge I
- Issue date: 2020 Mar
- The dominance of Big Pharma: unhealthy relationships?
- Authors: Badcott D, Sahm S
- Issue date: 2013 May
- Access to medication and drug company sales practices: setting priorities for critique and advocacy.
- Authors: Seiler N
- Issue date: 2003 Summer